Wellington Management Group LLP Has $126.80 Million Position in Adaptive Biotechnologies Corporation $ADPT

Wellington Management Group LLP lifted its position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 53.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,911,366 shares of the company’s stock after purchasing an additional 2,053,944 shares during the period. Wellington Management Group LLP’s holdings in Adaptive Biotechnologies were worth $126,799,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of ADPT. Bank of America Corp DE acquired a new stake in Adaptive Biotechnologies in the 2nd quarter valued at about $37,109,000. Freestone Grove Partners LP bought a new stake in Adaptive Biotechnologies in the second quarter valued at approximately $18,912,000. Odyssean LLC raised its stake in Adaptive Biotechnologies by 320.1% in the second quarter. Odyssean LLC now owns 67,709 shares of the company’s stock valued at $1,452,000 after buying an additional 51,592 shares during the period. Man Group plc bought a new position in shares of Adaptive Biotechnologies during the 2nd quarter worth approximately $1,972,000. Finally, Polar Asset Management Partners Inc. bought a new position in shares of Adaptive Biotechnologies during the 2nd quarter worth approximately $5,847,000. 99.17% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ADPT. Guggenheim increased their price target on Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Friday, July 17th. Piper Sandler increased their price objective on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. TD Cowen lifted their target price on shares of Adaptive Biotechnologies from $25.00 to $28.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.42.

Insider Buying and Selling

In related news, Director Robert Hershberg sold 30,664 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $24.40, for a total transaction of $748,201.60. Following the sale, the director owned 46,683 shares of the company’s stock, valued at $1,139,065.20. This represents a 39.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Harlan S. Robins sold 492,400 shares of Adaptive Biotechnologies stock in a transaction on Tuesday, July 21st. The shares were sold at an average price of $21.89, for a total value of $10,778,636.00. Following the completion of the transaction, the insider directly owned 812,058 shares of the company’s stock, valued at $17,775,949.62. This represents a 37.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 2,062,325 shares of company stock valued at $46,659,069 in the last quarter. Corporate insiders own 5.70% of the company’s stock.

Adaptive Biotechnologies Trading Down 2.3%

ADPT stock opened at $24.34 on Wednesday. Adaptive Biotechnologies Corporation has a 52 week low of $12.00 and a 52 week high of $26.87. The company has a market capitalization of $3.88 billion, a PE ratio of -59.37 and a beta of 2.08. The company’s 50-day simple moving average is $23.21 and its 200 day simple moving average is $17.79. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Wednesday, July 29th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The business had revenue of $71.55 million during the quarter, compared to analyst estimates of $65.44 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.Adaptive Biotechnologies’s revenue for the quarter was up 21.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.17) EPS. As a group, sell-side analysts anticipate that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current year.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.